...
首页> 外文期刊>Journal of Cancer Research and Therapeutics >Novel diagnostic biomarker for patients with Non-Hodgkin's Lymphoma by IgH gene rearrangement
【24h】

Novel diagnostic biomarker for patients with Non-Hodgkin's Lymphoma by IgH gene rearrangement

机译:Nigh基因重新排列的非霍奇金淋巴瘤患者的新型诊断生物标志物

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Aim of Study: Novel biomarkers for improving accuracy could be beneficial for disease monitoring and surveillance of Non-Hodgkin's lymphomas (NHL). So we explored the viability of analytical methods for identifying the rearranged immunoglobulin (Ig) H genes sequence. Materials and Methods: Next-generation sequencing (NGS) was used to sequence deoxyribonucleic acid (DNA) extracted directly from the tumor tissues of patients with NHL, and then specific rearranged DNA fragments from plasma was detected by polymerase chain reaction (PCR). Results: By parallel DNA capturing and sequencing of IgH genomic regions (IgCap), the sequence of rearranged IgH loci could be detected and precisely determined in tumor tissues of 12 patients with NHL. The circulating rearranged DNA fragments had been identified in the plasma of one patient. Conclusion: IgCap may be the favorable diagnostic method for patients with NHL in clinical.
机译:研究的目的:提高准确性的新型生物标志物可能是有益于疾病监测和非霍奇金淋巴瘤(NHL)的监测。因此,我们探讨了分析方法的可行性,用于鉴定重排免疫球蛋白(IG)H基因序列。材料和方法:下一代测序(NGS)用于序列直接从NHL患者的肿瘤组织萃取的脱氧核糖核酸(DNA),然后通过聚合酶链式反应(PCR)检测来自血浆的特异性重排的DNA片段。结果:通过并行DNA捕获和IGCAP的序列(IGCAP),在12例NHL的12例患者的肿瘤组织中,可以检测到重排座的序列。已经在一个患者的血浆中鉴定了循环重排的DNA片段。结论:IGCAP可能是临床NHL患者的有利诊断方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号